antibiotics tested had synergistic effects on the inhibitory activity of FTM-A against one strain of P. aeruginosa. Addition of a sublethal concentration of carbenicillin resulted in a significant increase in the rate of bacterial killing of FTM-A against P. aeruginosa. The antibacterial activity of FTM-A against 50 gentamicin-susceptible and 50 gentamicin-resistant clinical isolates of P. aeruginosa was clearly enhanced by addition of a subinhibitory concentration of carbenicillin or piperacillin.
Fortimicin A (FTM-A), a new aminoglycoside antibiotic containing the novel aminocycitol fortamine, is highly active in vitro and in vivo against most gram-positive and gram-negative bacteria (4, 8) . FTM-A retains this activity against most aminoglycoside-resistant strains (7, 8) , but it has relatively weak activity against Pseudomonas aeruginosa isolates (4). In vitro synergism has been demonstrated with combinations of carbenicillin and aminoglycoside antibiotics (1, 2, 5, 6, 9) . The present studies have been carried out in an attempt to explore possible synergistic relationships of FTM-A with ,Blactam antibiotics against P. aeruginosa strains.
MATERIALS AND METHODS
Antibiotics. The antibiotics used in this study included FTM-A (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan), cefsulodin (Takeda Chemical Industries, Ltd., Osaka, Japan), cefoperazone (Toyama Chemical Co., Ltd., Toyama, Japan), piperacillin (PIPC, Toyama Chemical Co.), cefotaxime (Hoechst-Roussel, Frankfurt, West Germany), ER 6120 (a new synthetic cephalosporin; Eizai Co., Ltd., Tokyo, Japan), apalcillin (Sumitomo Chemical Co., Ltd., Osaka, Japan), carbenicillin (CBPC; Beecham Pharmaceuticals, Betchworth, England), and gentamicin (GM; Schering Corp., Bloomfield, N.J.).
Strains. The strains used were P. aeruginosa GN3054/ML4262 (7) , an FTM-A-resistant strain producing AAC (3) 
RESULTS
MICs by the checkerboard method. Figure  1 shows the results of FTM-A or GM in combination with CBPC against P. aeruginosa GN3054/ML4262. Each of the two-drug combinations showed synergism, and the degree of synergism in the combination of FTM-A and CBPC (fractional inhibitory concentration index, 0.38) was greater than that in the combination of GM and CBPC (fractional inhibitory concentration index, 0.50). The responses of P. aeruginosa strain 9 to the FTM-A in combination with ,B-lactam antibiotics are shown in Table 1 . In the two-drug combinations studied, the interaction of PIPC, CBPC, cefsulodin, apalcillin, or cefotaxime with FTM-A was synergistic and that of cefoperazone or ER6120 with FTM-A was additive.
Bactericidal effect. To define further the effects of FTM-A alone and in combination with CBPC, two strains of P. aeruginosa were studied by bacterial killing curves ( Fig. 2 and 3) . Against P. aeruginosa strain GN3054/M14262, which is an FTM-A resistant strain producing AAC(3)-I, the addition of a sublethal concentration of CBPC (one-fourth the MIC, i.e., 50 ,ug/ ml) resulted in a significant increase in the rate of bacterial killing of FTM-A. Against P. aeruginosa strain 9, the rate of bacterial killing was also clearly enhanced by the drug combination.
Antibacterial activity of FIM-A combined with CBPC or PIPC. Figure 4 shows the activities of FTM-A alone and combined with a subinhibitory concentration of CBPC (12.5 ,ug/ ml) or PIPC (0.78,ug/ml) against 50 GM-susceptible clinical isolates of P. aeruginosa (the concentrations of CBPC alone and PIPC alone required to inhibit the growth of 50% of the total number of tested strains [50% MICs] were 50 and 3.13 ug/ml, respectively). The activity of FTM-A against GM-susceptible P. aeruginosa isolates was clearly enhanced by the addition of a subinhibitory concentration of CBPC or PIPC; the 50% MICs of FTM-A alone and combined with CBPC and PIPC were 10, 5, and 5 ,tg/ml, respectively. Similar results were obtained when 50 GM-resistant clinical isolates (the 50% MICs of CBPC and PIPC alone were similar to those against GM-susceptible strains) were tested; in this examination, the 50% MICs of FTM-A alone and combined with CBPC and PIPC were 40, 25, and 12.5,ug/ml, respectively (Fig. 5) . DISCUSSION FTM-A, a new aminoglycoside antibiotic, has (4, 8) . FTM-A also has appreciable activity against aminoglycoside-resistant strains of gram-positive and gram-negative bacteria except strains producing AAC(3)-I (7, 8) . However, FTM-A has relatively weak activity against P. aeruginosa (4).
The present study suggests that the combi- 
